Baxdrostat and Molecular Imaging of Adrenal Cytoreduction in Primary Aldosteronism

Summary

The goal of this clinical trial is to find out whether treatment with baxdrostat changes aldosterone-producing activity in the adrenal glands of people with primary aldosteronism. The study will use specialised imaging to measure changes in the adrenal glands before and after treatment. Participants will receive baxdrostat for 24 weeks and will be followed for changes in their adrenal imaging, blood pressure and hormone levels. The study will also investigate whether changes caused by treatment continue after baxdrostat is stopped. This is a single-group study, meaning that all participants receive baxdrostat and there is no placebo or comparison group.

Timeline

Start

2026-09-15

Primary completion

2028-05-31

Completion

2028-05-31

Drugs

Indications